The Golden Lounge

[Theo]

CC later this quarter on the deal: Palatin Technologies to Hold Call Following Closing of Licensing Agreement for North American Rights to Rekynda™

"CRANBURY, N.J., Jan. 10, 2017 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced that after the closing of its licensing agreement with AMAG Pharmaceuticals, Inc. (AMAG) for exclusive North American rights to develop and commercialize Rekynda™ (bremelanotide), an investigational product designed for on-demand treatment of hypoactive sexual desire disorder (HSDD) in pre-menopausal women, it will hold a conference call and audio webcast to discuss the licensing agreement and next steps for Palatin. The licensing agreement is expected to close in the first quarter of calendar year 2017.

The call will discuss Palatin's role in further development and regulatory approval of Rekynda, and potential licensing transactions outside North America. The call will also discuss Palatin's anticipated next steps in its other drug development programs, including its melanocortin receptor-­1 agonist peptides for treatment of inflammatory and dermatologic disease indications, melanocortin receptor-4 agonist compounds for treatment of obesity and diabetes, and natriuretic peptide receptor-­A agonist compounds for treatment of cardiovascular and pulmonary indications.

Palatin will announce the date and time of its conference call and audio webcast shortly after closing of the licensing agreement with AMAG Pharmaceuticals.

About Palatin Technologies

Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin's website at www.palatin.com.

Rekynda™ is a trademark of Palatin Technologies, Inc."